HDM2002 (Mitazalimab)
Metastatic Pancreatic Cancer
Key Facts
About Huadong Medicine (HD Medicine)
Huadong Medicine's mission is to become a global leader in pharmaceutical innovation, improving human health through the discovery and delivery of high-quality medicines. The company has achieved significant scale as one of China's largest and most valuable publicly traded pharma firms, with a robust commercial portfolio and a maturing R&D pipeline. Its strategy hinges on a dual approach: deepening its presence in the massive domestic market through commercialization and partnerships, while advancing a proprietary pipeline of novel biologics and small molecules to compete globally. Sustained high R&D investment and strategic business development are central to this growth plan.
View full company profileAbout Huadong Medicine (HD Medicine)
Huadong Medicine's mission is to become a global leader in pharmaceutical innovation, improving human health through the discovery and delivery of high-quality medicines. The company has achieved significant scale as one of China's largest and most valuable publicly traded pharma firms, with a robust commercial portfolio and a maturing R&D pipeline. Its strategy hinges on a dual approach: deepening its presence in the massive domestic market through commercialization and partnerships, while advancing a proprietary pipeline of novel biologics and small molecules to compete globally. Sustained high R&D investment and strategic business development are central to this growth plan.
View full company profileTherapeutic Areas
Other Metastatic Pancreatic Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| MesoPher | Amphera | Phase 2 |
| ABTL0812 (Ibrilatazar) | Ability Pharma | Phase 2b |